PsychedelicNewsBreaks Archive - Page 39 of 69

TuesdayNov 02, 2021 10:32 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules R&D Briefing to Release Breakthrough Research Findings

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be hosting an in-person and virtual research and development briefing. Scheduled for Nov. 8, 2021, from 8:30–9:30 a.m. EST, the briefing is slated to include breakthrough preclinical, research findings that indicate advancements in the company’s focus on creating a promising approach for patients in need of effective and safe prescription therapies in the mental health space. Cybin CEO Doug Drysdale and other key members of the company’s senior scientific research team will be hosting the event, which will be held during the Wonderland Conference in Miami;…

MondayNov 01, 2021 12:21 pm

PsychedelicNewsBreaks – IBN and PsychedelicNewsWire to Broaden Reach for Upcoming Wonderland Miami Conference

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announced that it, together with its PsychedelicNewsWire (“PNW”) brand, will further collaborate with Microdose Psychedelic Insights for the upcoming Wonderland Miami Conference. The event is slated to take place at Miami’s Adrienne Arsht Center for the Performing Arts on Nov. 8-9, 2021. The premier destination for the psychedelic industry, Wonderland: Miami provides an ideal opportunity to connect with influential leaders in science, policy and business. Roger McIntyre, M.D., FRCPC CEO and director, Braxia Scientific (ICX: BRAX), Lamar Odom, former professional American basketball player, and Zappy Zapolin, psychedelic concierge, are among…

MondayNov 01, 2021 11:39 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Way Through Unique Psychedelic Drug Development Focus

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is nearing the launch of a phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (“PWS”), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction. Tryp also plans to execute phase 2b clinical trials for its proprietary psychedelic candidate TRP-8803 to evaluate its ability to penetrate the natural blood-brain barrier and effectively alleviate pain and addiction concerns, including targets for phantom limb pain and fibromyalgia. “Tryp’s product development moves beyond…

ThursdayOct 28, 2021 12:36 pm

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Enters Strategic LOI to Distribute Ketamine Protocol

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has signed a nonbinding letter of intent with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF). Awakn is a biotechnology company with clinical operations focused on researching, developing and delivering psychedelic medicine to better treat addiction. According to the agreement, MINDCURE will distribute Awakn’s ketamine-assisted psychotherapy for alcohol use disorder protocol via its digital therapeutics platform, iSTRYM. Distribution began in August when MINDCURE released the minimum viable product version of iSTRYM into partner clinics across North America with full commercial deployment to all partner clinics slated for…

ThursdayOct 28, 2021 11:04 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unveils Psychedelic Facilitator Training Program Based on Groundbreaking Psychotherapy Approach

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is launching its own psychedelic facilitator training program. Called EMBARK, the project is led by expert faculty and provides psychedelic clinical trial facilitators with fundamental training to provide skillful, ethical care to individuals receiving psychedelic treatment. EMBARK emphasizes experiential learning and includes an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state as well the training and practice sessions on the EMBARK model, a groundbreaking psychotherapy approach that incorporates psychedelic medicine with leading clinical approaches designed to promote supportive healing.…

WednesdayOct 27, 2021 11:11 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speakers for World’s Premiere Psychedelic, Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that COMPASS Pathways execs George Goldsmith and Ekaterina Malievskaia MD will be featured speakers at next month’s Meet Delic event. Meet Delic is a revolutionary, two-day immersive edutainment experience designed to gather together the world's leading psychedelic and wellness thought and business leaders. The two-day event is scheduled for Nov. 6–7, 2021, in Las Vegas. Goldsmith, CEO and cofounder of COMPASS Pathways, and Malievskaia, also cofounder and chief innovation officer, will participate in a keynote interview focused on exploring the company’s…

WednesdayOct 27, 2021 10:24 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Successfully Synthesizes Novel Psilocin Analogue

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has successfully synthesized a novel psilocin analogue, a tryptamine. This achievement means improved pharmaceutical properties to further strengthen MYCO’s library of patent-pending tryptamines. According to the announcement, the synthesis of the tryptamine results in the company adding a new compound to its growing library of compounds, supporting Mydecine’s commitment to improve the safety and efficacy of its drug-development candidates for use in therapy and medical practice. Since 2021 Mydecine has been working with Applied Pharmaceutical Innovation…

WednesdayOct 27, 2021 10:22 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Sponsor, Participate In Upcoming Events

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, announced its participation in two upcoming November events. The company will be a silver sponsor of Wonderland Miami, the largest in-person conference focused on the psychedelic medicine industry. At Wonderland, MINDCURE president and CEO Kelsey Ramsden will participate in several panel discussions scheduled during the in-person, two-day event. Slated for Nov. 8–9, 2021, Wonderland Miami is presented by Microdose Psychedelic Insights, a portfolio company of Origin Therapeutics. In addition, MINDCURE is also scheduled to participate in next month’s International Summit on Psychedelic Therapies for…

TuesdayOct 26, 2021 1:54 pm

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Enters Agreement with Aragen Life Sciences to Produce Innovative Drug Candidate

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced its entry into a development and supply agreement with Aragen Life Sciences Pvt. Ltd for the production of its innovative molecule, 5-Methoxy-2-aminoindane (“MEAI”). Aragen is a global leader in providing discovery, development and manufacturing solutions for life sciences firms under Good Manufacturing Practices. Under the agreement, Aragen will complete a process optimization and synthesis, manufacturing and supply of MEAI to Clearmind. “Aragen is a world-class, life-sciences company with state-of-the-art manufacturing…

TuesdayOct 26, 2021 1:29 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the company’s sponsored feasibility study. The study focuses on using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The word psychedelic means ‘mind-manifesting,’ but what has been missing is useful ‘mind-imaging’—the ability to dynamically trace the neural correlates of human conscious experience,” said Cybin’s Chief Clinical Officer Dr. Alex Belser. “Conventional neuroimaging just isn’t dynamic enough to study the psychedelic experience…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks